Advisory Board

Dr. Ashok Amin, PhD

Dr. Ashok Amin is currently Adjunct Professor Biomedical Engineering at Virginia Tech, CEO at Rheumatrix Inc and Co-Editor-in-Chief of J. Molecular Signalling Updates, Revoltech Press. He has been the Vice president of research and development and member of management council at Advaxis Immunotherapies Inc. and Carilion Clinic in Roanoke, Virginia. He has also held an impressive range of academic positions as Director of Rheumatology Research at the Hospital for Joint Diseases at New York University (NYU), Professor and Chairman of the Department of Genetics and Director of Translational Research at the Virginia College of Medicine.He has acted as a collaborator or consultant to 17 different international pharmaceutical companies, including Schering-Plough, DuPont-Merck, Yamanouchi [Astellas] Pharmaceuticals, Roche, Procter & Gamble Pharm. Co, Ranbaxy Laboratories Ltd, CollaGenex Pharmaceuticals, and Forest Laboratories.He has been earned several distinguished awards such as Fellow of the Department of Atomic Energy, India; Young Investigator Award from the National Institute of Health, USA; Distinguish Investigator from the Dept. of Medicine, NYU; Tibor Fabian Award for Excellence in Science; Young Scholar Award--Arthritis Foundation; USA and several others.He has served on over 32 editorial boards or as an ad hoc reviewer for many leading scientific publications including Journal of Immunology, Nature, The New England Journal of Medicine, Science and The Wall Street Journal. He has acted as investigator or administrator on over 40 clinical trials, obtained 22 patents and authored over 90 peer-reviewed journal articles, reviews and book chapters.He has led several international multidisciplinary research teams and created scalable and high impact models for commercialization of intellectual property with international partners and venture capital firms. Dr. Amin's team discovered the drug ORACEATM (doxycycline, USP), which is currently being marketed by Galderma for the treatment of rosacea. He has procured over 50 research grants and contracts to propel his research in microbiology, biochemistry, immunology, genomics, cancer and inflammatory diseases.He procured a Ph.D. in Microbiology from Department of Microbiology and Biotechnology, MSU, Baroda, India. He completed his post-doctoral fellowship at New York University School of Medicine in Immunology, where he also joined as an Assistant Professor of Pathology.

Dr. D Sengupta, PhD

Dr Sengupta has several decades of research experience in cancer chemotherapy, synthetic antibiotics and pesticides. Presently he serves as an advisor to the Secretary, Department of Scientific and Industrial Research (DSIR) and Director General, Council of Scientific and Industrial Research (CSIR). He also acts as a senior advisor to Confederation of Indian Industry (CII) to oversee the Life science group. He has served in senior positions in several organizations like Central Drug Research Institute (CDRI) and was responsible for developing and transferring technologies of Amoxycillin, Cephelexin and 6-APA to industry, Hindustan Unilever Limited, JK Industries to name a few.At Union Carbide Research centre, Bhopal he developed technologies on Carbaryl and Aldicarb which were taken up for worldwide promotion research.He was responsible for setting up the first residue laboratory in the country. He was a DuPont visiting fellow at Georgia Institute of Technology. His most outstanding contribution was the setting up of Parry Technology Centre and 1000 mt export oriented facility in Shanghai. He served as Director at Institute of Pesticide Formulation Technology and was coordinating with six centres in the Asia Pacific Region under the ongoing RENPAP Program and also coordinating the Chemical Weapons Program. Dr. Sengupta received his PhD from CDRI, Lucknow in 1971 on cancer chemotherapy and post-doctoral degree from Massachusetts Institute of Technology (MIT).